Tobi Generic Name & Formulations
Mechanism of Action
Tobi Dosage and Administration
Adults and Children
Tobi Boxed Warnings
Safety and efficacy have not been demonstrated in patients <6yrs, in those with FEV1 <25% or >75% predicted, or patients colonized with B. cepacia. Auditory/vestibular dysfunction; monitor closely; if ototoxicity occurs, manage and discontinue if appropriate. Risk for ototoxicity (known maternal history of ototoxicity due to aminoglycoside use or mitochondrial DNA variants); consider alternative therapies. Consider obtaining audiometric evaluations at baseline (esp. at risk of auditory dysfunction). Monitor for high frequency hearing loss if tinnitus occurs. Renal dysfunction or neuromuscular disorders (eg, myasthenia gravis, Parkinson's disease); monitor closely. Monitor serum tobramycin levels in renal dysfunction patients or if treated with concomitant IV aminoglycosides. Consider discontinuing if nephrotoxicity occurs. Elderly. Embryo-fetal toxicity. Pregnancy. Nursing mothers: monitor infant.
The bioavailability of Tobi may vary because of individual differences in nebulizer performance and airway pathology. Following administration of Tobi, tobramycin remains concentrated primarily in the airways.
Following administration of Tobi, tobramycin remains concentrated primarily in the airways. Binding of tobramycin to serum proteins is negligible.
Tobi Adverse Reactions
Tobi Clinical Trials
Tobi Patient Counseling